PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
17536270-4	2007	vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) were detected in back skin in both the tacrolimus group and the minoxidil group, but not in the vaseline group.	Tacrolimus	116-126	vascular endothelial growth factor A	Mus musculus	0-34	
17536270-4	2007	vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) were detected in back skin in both the tacrolimus group and the minoxidil group, but not in the vaseline group.	Tacrolimus	116-126	vascular endothelial growth factor A	Mus musculus	36-40	
17536270-5	2007	CONCLUSION: Tacrolimus can promote the growth of hair by stimulating the hair follicle to enter anagen V in mice, which may be explained by the effects of VEGF and HGF.	Tacrolimus	12-22	vascular endothelial growth factor A	Mus musculus	155-159	
23613708-10	2013	Although the expression of Vegfa (p<0.05) and Ccnd1 (p<0.05) was significantly upregulated in the tacrolimus-treated group compared with that of the control group, no differences were observed between the groups in terms of other types of gene expression.	Tacrolimus	104-114	vascular endothelial growth factor A	Mus musculus	27-32	
19148552-0	2009	Tacrolimus but not cyclosporine A enhances FGF-2-induced VEGF release in osteoblasts.	Tacrolimus	0-10	vascular endothelial growth factor A	Mus musculus	57-61	
19148552-3	2009	In the present study, we investigated the effects of tacrolimus (FK506) and cyclosporine A, well-known immunosuppressants, on the FGF-2-induced VEGF release in these cells.	Tacrolimus	53-63	vascular endothelial growth factor A	Mus musculus	144-148	
19148552-3	2009	In the present study, we investigated the effects of tacrolimus (FK506) and cyclosporine A, well-known immunosuppressants, on the FGF-2-induced VEGF release in these cells.	Tacrolimus	65-70	vascular endothelial growth factor A	Mus musculus	144-148	
19148552-4	2009	Tacrolimus, but not cyclosporine A which alone had no effect on VEGF basal levels, significantly enhanced FGF-2-stimulated VEGF release.	Tacrolimus	0-10	vascular endothelial growth factor A	Mus musculus	123-127	
19148552-6	2009	SP600125, a specific inhibitor of SAPK/JNK, reduced the amplification by tacrolimus of the FGF-2-induced VEGF release.	Tacrolimus	73-83	vascular endothelial growth factor A	Mus musculus	105-109	
19148552-8	2009	These results strongly suggest that tacrolimus enhances FGF-2-stimulated VEGF release via up-regulation of SAPK/JNK through modulating p70 S6 kinase in osteoblasts.	Tacrolimus	36-46	vascular endothelial growth factor A	Mus musculus	73-77	
23032068-6	2012	FK506 treatment significantly lowered retinal TNF-a, VEGF, iNOS and COX-2.	Tacrolimus	0-5	vascular endothelial growth factor A	Mus musculus	53-57	
20073093-0	2009	Topical tacrolimus suppresses the expression of vascular endothelial growth factor and insulin-like growth factor-1 in late anagen.	Tacrolimus	8-18	vascular endothelial growth factor A	Mus musculus	48-82